| Literature DB >> 32456086 |
Paolo Santambrogio1, Maddalena Ripamonti2, Chiara Paolizzi2, Celeste Panteghini3, Miryam Carecchio3,4, Luisa Chiapparini5, Marzia Raimondi2, Alicia Rubio6, Ivano Di Meo3, Anna Cozzi1, Stefano Taverna1, Giuseppe De Palma7, Valeria Tiranti3, Sonia Levi1,2.
Abstract
Pantothenate Kinase-associated Neurodegeneration (PKAN) belongs to a wide spectrum of diseases characterized by brain iron accumulation and extrapyramidal motor signs. PKAN is caused by mutations in PANK2, encoding the mitochondrial pantothenate kinase 2, which is the first enzyme of the biosynthesis of Coenzyme A. We established and characterized glutamatergic neurons starting from previously developed PKAN Induced Pluripotent Stem Cells (iPSCs). Results obtained by inductively coupled plasma mass spectrometry indicated a higher amount of total cellular iron in PKAN glutamatergic neurons with respect to controls. PKAN glutamatergic neurons, analyzed by electron microscopy, exhibited electron dense aggregates in mitochondria that were identified as granules containing calcium phosphate. Calcium homeostasis resulted compromised in neurons, as verified by monitoring the activity of calcium-dependent enzyme calpain1, calcium imaging and voltage dependent calcium currents. Notably, the presence of calcification in the internal globus pallidus was confirmed in seven out of 15 genetically defined PKAN patients for whom brain CT scan was available. Moreover, we observed a higher prevalence of brain calcification in females. Our data prove that high amount of iron coexists with an impairment of cytosolic calcium in PKAN glutamatergic neurons, indicating both, iron and calcium dys-homeostasis, as actors in pathogenesis of the disease.Entities:
Keywords: NBIA (neurodegeneration with brain iron accumulation); PKAN (pantothenate kinase-associated neurodegeneration); calcium; iPSC (induced pluripotent stem cells); iron; neurodegeneration
Mesh:
Substances:
Year: 2020 PMID: 32456086 PMCID: PMC7279353 DOI: 10.3390/ijms21103664
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Characterization of iPS-derived neurons. (a) An example of iPS-derived neurons from control and one Pantothenate Kinase-associated Neurodegeneration (PKAN) patient. They were stained for neuronal markers: microtubule associated protein 2 (Map2), the vesicular glutamate transporter 1 (VGlut1) and the nuclear stain Hoechst. Scale bar 20 µm. (b) Plot representing the percentage of the VGlut1 positive cells. (c) Iron quantification by inductively coupled plasma mass spectrometry in cell lysates. * p < 0.05 (Kruskal-Wallis test). (d) Representative images of ultrastructural analysis of fixed neurons examined with electron microscope. Scale bar 500 nm. Arrows point to electron dense granules present in mitochondria. (e) Left panel, mitochondrial aggregates were counted in each mitochondria in >30 field (200 mitochondria total) for each sample. * p < 0.05; ** p < 0.01, (one-way ANOVA). Right panel, plot of the mitochondria with at least 3 dots. * p < 0.05 (Student’s t-test). (f) Percentage of mitochondria with or without dots in fibroblasts, in Neuronal Precursor Cells (NPCs) and iPS-derived neurons. ** p < 0.01 (two-way Anova). All data are presented as mean + SEM on at least three independent replicates.
Figure 2Electron spectroscopic imaging (ESI) analysis on PKAN iPS-derived neurons. (a) Representative images of ultrastructural analysis of mitochondria from fixed iPS-derived neurons examined with electron microscope. (b) Overlapping of the map obtained by ESI in which calcium is evidenced in red and of the same field visible in A. (c,d) Overlapping of the map obtained by ESI analysis in which calcium or phosphorus are respectively evidenced in red. Arrows point to electron dense granules present in mitochondria. Scale bar 500 nm.
Figure 3Analysis of the product (cut spectrin) of calcium-dependent calpain1 enzymatic activity. (a) Immunoblotting probed with antibody specific for spectrin on neuronal precursor cells (NPCs) and (b, top panel) on iPS derived-neurons (20 µg of total proteins). The asterisks indicate non-specific bands. (b, lower panel) Immunoblotting probed with antibody specific for calpain1 on iPS derived-neurons. β-actin was used as loading control in all the immunoblotting. Graph of the ratio of cut spectrin/total spectrin in neuronal precursor cells and in iPS derived-neurons and of calpain1/β-actin in iPS derived-neurons are shown on the right side of the respective blotting. The statistical analysis was conducted using student-t-test: * p < 0.05, ** p < 0.01. All data are presented as mean + SEM on at least three independent replicates.
Figure 4Fura Red qualitative/quantitative analysis of the cytosolic calcium content in iPS-derived neurons. (a) An example of graph of the analysis with the Fura Red AM probe in control and PKAN [Gly420Valfs*30]a iPS derived-neurons. (b) Graph showing the cytosolic calcium concentration in basal conditions obtained by measuring the fluorescence ratio of Fura Red following excitation at 405/488 nm and calculated on a calibration curve. (c) Graph showing the levels of cytosolic calcium, after addition of ionomycin, obtained by measuring the increase in fluorescence at the peak compared to baseline. (d) Graph showing the levels of cytosolic calcium, after addition of ionomycin, obtained by measuring the increase in fluorescence at the plateau compared to baseline. The statistical analysis was done using in a two-way ANOVA; in (b) one-way ANOVA; in (c) and (d) Student’s t-test: * p < 0.05, ** p < 0.01. All data are presented as mean + SEM on at least three independent replicates.
Figure 5Voltage-dependent calcium currents recorded in iPS-derived neurons. (a) Example of calcium currents recorded in voltage-clamp at depolarizing levels from -60 to +30 mV in control (CTR) and PKAN iPS derived-neurons after 28 days from the start of differentiation. The right panel shows magnified portions of calcium currents included in gray boxes on the left. (b,c) Current-to-voltage plots from control and PKAN iPS derived-neurons 28 (panel b) and 60 (panel c) days after the start of the differentiation. Statistical analysis was performed using one-way ANOVA (* p < 0.05, ** p < 0.01). All data are presented as mean + SEM on at least three independent replicates (controls at 28 days = 40 cells; PKAN at 28 days = 14 cells. Controls at 60 days = 12 cells; PKAN at 60 days = 9 cells).
PKAN patients subjected to CT scan.
| Patient’s Code (Sex) | PANK2 Mutations $ (cDNA) | PANK2 Mutations $ (Protein) | Date of CT Scan | Globi Pallida Calcifications | DBS | Date of Brain MRI | Age of Disease Onset |
|---|---|---|---|---|---|---|---|
| mt4245 (f) | c.[821_822delCT]; | p.[Leu275Valfs*16]; | 2014 | bilateral rock calcifications | DBS | 2006; 2013 | 2 years |
| HA44 (f) | c.[1069C > T]; | p.[Arg35Trp]; | 2013; 2015 | bilateral rock calcifications | DBS | 2008; 2009 | 24 years |
| HA143 (f) | c.[965A > G]; | p.[Glu322Gly]; | 2015 | bilateral rock calcifications | DBS | 2006; 2015 | 16 years |
| HA31 (f) | c.[821_822delCT]; | p.[Leu275Valfs*16]; | 2000 | bilateral rock calcifications | 2001; 2002 | 1 year | |
| HA26 (m) | c.[1441C > T]; | p.[Arg481*]; | 2017 | no calcifications | 2014; 2015; 2017 | 17 years | |
| HA35 (m) | c.[790C > T]; | p.[Arg264Trp]; | 2015 | bilateral calcifications | NA | 2008; 2009 | NA |
| HA101 (f) | c.[1259delG]; | p.[Gly420Valfs*30]; | 2007 | bilateral calcifications | 2007; 2008; 2009 | 4 years | |
| HA102 (m) | c.[1259delG]; | p.[Gly420Valfs*30]; | 2007 | no calcifications | 2007; 2008; 2009; 2013 | 7 years | |
| HA134 (m) | c.[1499A > T]; | p.[Asn500Ile]; ? | 2008 | no calcifications | 2004; 2008 | 2 years | |
| mt4597 (m) | c.[683T > C]; | p.[Phe228Ser]; | 2013 | no calcifications | DBS | 2006; 2008; 2011 | 2 years |
| HA167 (m) | c.[821_822delCT]; | p.[Leu275Valfs*16]; | 2011 | no calcifications | 2009; 2010; 2011 | 9 years | |
| HA316 (f) | c.[821_822delCT]; | p.[Leu275Valfs*16]; | 2015 | bilateral slight calcifications | 2005 (normal); | 18 months | |
| HA185 (f) | c.[36T > A]; | p.[His12Gln]; | 2010 | no calcifications | 2010; 2011; 2012; 2015; 2019 | 12 years | |
| BDM862 (f) | c.[1236-1G > A]; | p.?;[Gly521Arg] | 2015; 2017 | no calcifications | 2015; 2016 | 5 years | |
| LDM709 (m) | c.[982-1G > A]; | p.?;[Gly521Arg] | 2019 | no calcifications | 2017; 2019 | 8 years |
Patients identified by code, sex and mutations. Calcification, deep brain stimulation (DBS), date of CT scan and brain MRI, and age of onset are indicated. $ Following the HGVS-nomenclature [20], PANK2 reference sequence NM_153638. ? = unknown effect of the mutation on the protein.
Figure 6Imaging studies on in vivo PKAN patients’ brains. (a) Axial CT and (b) T2-w MR images show bilateral rock calcifications in the globi pallidi, corresponding to the strong hypointensity into the antero-medial portion hyperintensity of the eye-of-the-tiger sign (white arrows). (c) Axial CT, (d) T2-w and (e) GRE MR images, demonstrate that the slight calcifications (white arrows) lie into the antero-medial portion hyperintensity of the globi pallidi (black arrows), right in front of the back portion of the nuclei where there is iron deposition (star). (f–h) Graphical representation of the distribution of male and female and of calcified and non-calcified patients.